" class="no-js "lang="en-US"> Sosei Archives - Medtech Alert
Monday, May 20, 2024

Sort by:

Date

Top Post

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]

Pfizer Progresses its Oral Receptor into Phase 2 Clinical Trials for Treating Type 2 Diabetes and Obesity

Sosei Group Corporation, the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design […]

Neurocrine Biosciences and Sosei Heptares Announce Collaboration to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other Neuropsychiatric Disorders

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Sosei Group Corporation (“Sosei Heptares“; TSE: 4565) announce the signing […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more